EDITAS MEDICINE INC.

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

03 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

02 Nov 2023 08:12:24 By Nasdaq GlobeNewswire

Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

27 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

16 Oct 2023 07:00:01 By Nasdaq GlobeNewswire

Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

25 Sep 2023 15:30:00 By Nasdaq GlobeNewswire

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

25 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Upcoming Investor Events

30 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Second Quarter 2023 Results and Business Updates

02 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization

27 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update

26 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Pricing of Offering of Common Stock

14 Jun 2023 21:06:40 By Nasdaq GlobeNewswire

Editas Medicine Announces Offering of Common Stock

14 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial

09 Jun 2023 02:00:00 By Nasdaq GlobeNewswire

Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia

06 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Editas Medicine Reports Inducement Grant to New Chief Financial Officer

18 May 2023 15:30:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer

16 May 2023 15:30:00 By Nasdaq GlobeNewswire

Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

11 May 2023 09:32:40 By Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2023 Results and Business Updates

05 May 2023 06:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data

01 May 2023 15:01:00 By Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events

01 May 2023 05:45:00 By Nasdaq GlobeNewswire